AC Immune stock jumps 20% on data for Parkinson's disease drug
AC Immune (ACIU) stock shot up 20% Thursday after the company reported positive data from a Phase 2 study of its drug ...
AC Immune’s Promising Trial Results for Parkinson’s Therapy
AC Immune SA (ACIU) has released an update. AC Immune SA announced promising interim results from its Phase 2 trial of the ACI-7104.056 ...
Benzinga.com13h
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
reinforces the best-in-class characteristics of our clinically validated anti-a-syn active immunotherapy for the treatment of ...
WebMD28d
FDA Approves New Treatment for Advanced Parkinson’s Disease
Oct. 18, 2024 -- The FDA has approved a new injectable treatment for adults with advanced Parkinson’s disease called Vyalev (also known as Produodopa). This new option is designed to help people ...
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s Disease
AC Immune Reports Positive Interim Results from Phase 2 Trial of ACI-7104.056 Active Immunotherapy in Early Parkinson’s DiseaseActive ...
New drug targets for Alzheimer's identified from cerebrospinal fluid
A multitude of genes have been linked to the development of Alzheimer's disease. Specifically how those genes might influence ...
Medical Xpress23d
FDA approves Vyalev for advanced Parkinson's disease
for adults living with advanced Parkinson's disease (PD). Vyalev is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in ...
USA Today28d
Injectable drug to ease advanced Parkinson's disease symptoms approved by FDA
The Food and Drug Administration approved a drug produced by AbbVie for the treatment of late stage Parkinsons disease the company announced Thursday. The regulator approved Vyalev, also known as ...